Last reviewed · How we verify

Jemperli (DOSTARLIMAB)

GSK · FDA-approved approved Monoclonal antibody Quality 55/100

Dostarlimab-gxly binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, enhancing the immune response against tumors.

Jemperli (Dostarlimab) is a programmed death receptor-1 (PD-1) blocking antibody developed by GlaxoSmithKline. It works by blocking the PD-1 receptor on immune cells, allowing them to recognize and attack cancer cells. Jemperli is approved for the treatment of recurrent or advanced endometrial cancer. It is a patented product, and its commercial status is owned by GlaxoSmithKline. Key safety considerations include immune-mediated adverse reactions and gastrointestinal toxicity.

At a glance

Generic nameDOSTARLIMAB
SponsorGSK
Drug classProgrammed Death Receptor-1 Blocking Antibody [EPC]
TargetPD-1
ModalityMonoclonal antibody
Therapeutic areaOncology
PhaseFDA-approved
First approval2021
Annual revenue800

Mechanism of action

Dostarlimab-gxly works by binding to the PD-1 receptor on T cells, preventing it from interacting with its ligands PD-L1 and PD-L2. This blockage releases the inhibition of T-cell activity, allowing the immune system to better recognize and attack tumor cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
SEC EDGARRevenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: